Table 1.
Demographic and clinical data of the study participants
| PD | NC | ET | P value | |
|---|---|---|---|---|
| Overall subjects | ||||
| Number | N = 107 | N = 49 | N = 41 | |
| Gender[male/female] | 48/59 | 18/31 | 18/23 | 0.625 |
| Age[years] | 62.1 ± 0.8 | 61.9 ± 1.2 | 60.0 ± 1.9 | 0.515 |
| Disease duration[years] | 5.0 ± 0.4 | NA | 9.8 ± 1.3 | 0.003** |
| LEDD (mg) | 311.2 | NA | NA | |
| Subjects with right affected side | ||||
| Number | N = 74 | N = 49 | ||
| Gender[male/female] | 33/41 | 18/31 | 0.386 | |
| Age[years] | 62.4 ± 1.0 | 61.9 ± 1.2 | 0.662 | |
| Subjects with left affected side | ||||
| Number | N = 75 | N = 49 | ||
| Gender[male/female] | 32/43 | 18/31 | 0.510 | |
| Age[years] | 62.8 ± 1.0 | 61.9 ± 1.2 | 0.490 | |
| Subgroup of PD (FT = 1) vs.NC | ||||
| Subjects with right affected side | ||||
| Number | N = 19 | N = 49 | ||
| Gender[male/female] | 7/12 | 18/31 | 0.993 | |
| Age[years] | 61.9 ± 2.1 | 61.9 ± 1.2 | 0.995 | |
| Subjects with left affected side | ||||
| Number | N = 30 | N = 49 | ||
| Gender[male/female] | 13/17 | 18/31 | 0.560 | |
| Age[years] | 62.3 ± 1.7 | 61.9 ± 1.2 | 0.705 | |
| Subgroup of PD (FT = 2) vs.NC | ||||
| Subjects with right affected side | ||||
| Number | N = 38 | N = 49 | ||
| Gender[male/female] | 18/20 | 18/31 | 0.318 | |
| Age[years] | 63.6 ± 1.3 | 61.9 ± 1.2 | 0.389 | |
| Subjects with left affected side | ||||
| Number | N = 25 | N = 49 | ||
| Gender[male/female] | 8/17 | 18/31 | 0.687 | |
| Age[years] | 66.1 ± 1.5 | 61.9 ± 1.2 | 0.051 | |
| Subgroup of PD (FT = 3) vs.NC | ||||
| Subjects with right affected side | ||||
| Number | N = 17 | N = 49 | ||
| Gender[male/female] | 8/9 | 18/31 | 0.453 | |
| Age[years] | 60.5 ± 2.3 | 61.9 ± 1.2 | 0.809 | |
| Subjects with left affected side | ||||
| Number | N = 20 | N = 49 | ||
| Gender[male/female] | 11/9 | 18/31 | 0.163 | |
| Age[years] | 59.4 ± 1.7 | 61.9 ± 1.2 | 0.334 | |
| Subgroup of PD (H-Y = 1) vs.NC | ||||
| Subjects with right affected side | ||||
| Number | N = 18 | N = 49 | ||
| Gender[male/female] | 8/10 | 18/31 | 0.566 | |
| Age[years] | 60.2 ± 2.0 | 61.9 ± 1.2 | 0.457 | |
| Subjects with left affected side | ||||
| Number | N = 18 | N = 49 | ||
| Gender[male/female] | 8/10 | 18/31 | 0.566 | |
| Age[years] | 59.3 ± 1.9 | 61.9 ± 1.2 | 0.311 | |
Kruskal-Wallis test and Mann-Whitney U test were used to compare the continuous variables. The Chi-square test was used to compare the categorical variables. Data were expressed as numbers or as mean ± SE. ** P < 0.01
PD Parkinson’s disease, ET essential tremor, NC normal controls, H-Y modified Hoehn and Yahr stage, LEDD levodopa equivalent daily dose, NA not available